Cancel
Venatorx Pharmaceuticals
See Linkedin
Venatorx Pharmaceuticals Employees
15 people indexed:
-
u0wbzl@f22k2j52.h7z Sign up to see email
-
fpu14shfh@kqb4ysd7.pl5 Sign up to see email
-
Chitrananda Abeygunawardana
Vice President, Regulatory Affairs
4803z297z7k15l8@hh7i8kip.lh2 Sign up to see emailq9jhp8l8061l2p5@31z0i8ii.6q9 Sign up to see email -
Christopher J. Burns
Founder, President and Chief Executive Officer
y.608q6@d9l6hk8p.57d Sign up to see email6.154yd@pkl47331.6py Sign up to see email -
Daniel C. Pevear
Founder and Senior Vice President, Biology and Grants Development
y.qg9j2h@l9b30j6w.9q2 Sign up to see email4.5y1zj8@07suyg49.lw7 Sign up to see email -
7y8si@bfy8uldf.duz Sign up to see email
-
Jason Burdette
Senior Vice President, CMC and Technical Operations
6ppii2kg@zhki29kz.p99 Sign up to see email5k691k2j@jis78zgf.zf0 Sign up to see email -
fg352@y2f57ydg.bpy Sign up to see email
-
Jennifer Nelson
Senior Vice President, Strategic Planning and Operations
6u44d4@g8ikgjd6.pfp Sign up to see email1d6g3y@zi3gfd7p.075 Sign up to see email -
58pu.ugzk@lyy0wwz5.yu6 Sign up to see email
-
244uuuy7@8j2ukyzp.qhi Sign up to see email
-
1z8s0q@zk26z098.us3 Sign up to see email
-
f54959.86u9@j5j333lw.fw2 Sign up to see email
-
wykqf@5w65w98q.lpk Sign up to see email
-
95hul49@6802yp0w.0y9 Sign up to see email
Venatorx Pharmaceuticals Company Information
Venatorx Pharmaceuticals, established in June 2010, is dedicated to the discovery and development of novel anti-infectives aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. The company has built a robust in-house research and development organization and has filed over 120 patents. Venatorx’s lead asset, cefepime-taniborbactam, is an investigational antibiotic that has successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis, and is currently under FDA review. This asset has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA and is also being developed for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). In 2022, BARDA awarded Venatorx a Project Bioshield contract worth up to $318 million for the development and procurement of cefepime-taniborbactam. Additionally, Venatorx is developing an oral BL/BLI antibacterial, ceftibuten-ledaborbactam etzadroxil, which will advance directly to a global Phase 3 cUTI clinical trial under a new BARDA contract. This compound is designed to treat infections caused by drug-resistant Enterobacterales and has shown positive results in Phase 1 clinical trials. Venatorx is also pursuing discovery-stage programs in both antiviral and antibacterial fields, including a novel class of non-beta-lactam Penicillin Binding Protein (PBP) inhibitors. The company has received equity investments from Abingworth, the AMR Action Fund, BioAdvance, Foresite Capital, and Versant Ventures, along with significant funding awards from the Wellcome Trust, BARDA, CARB-X, DTRA, and NIAID. Venatorx has established license and collaboration agreements with Everest Medicines, GARDP, and Roche. Recognized as one of the ‘Best Places to Work’ by the Philadelphia Business Journal multiple times, Venatorx continues to make significant strides in the field of anti-infective drug development.
Report inaccurate information
Report inaccurate information
